2nd Quarter - Report — DALRYMPLE & ASSOCIATES, LLC for SANOFI PASTEUR (2014)

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm

DALRYMPLE & ASSOCIATES, LLC

Client

SANOFI PASTEUR

Income

$61,000

Expenses

—

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing	Filed	Amount	Counted
2nd Quarter - Report (this page)	Jul 21, 2014	$61,000	Replaced
2nd Quarter - Report	Oct 9, 2014	$46,000	Yes

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

Funding and appropriations for adult, childhood and biodefense vaccines and other medical countermeasures

Foreign entity interest: 100% Sanofi Pasteur Worldwide, 2 Avenue Point, F-69367, Lyon, France

Lobbyist	Covered position, as disclosed
DONALD DALRYMPLE New	Principal

Contacted: SENATE; Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); Centers For Disease Control & Prevention (CDC)

Health Issues HCR

Childhood, adult and biodefense vaccine issues

Foreign entity interest: 100% Sanofi Pasteur Worldwide, 2 Avenue Point, F-69367, Lyon, France

Lobbyist	Covered position, as disclosed
DONALD DALRYMPLE New	Principal

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Natl Institutes of Health (NIH); Food & Drug Administration (FDA); Centers For Disease Control & Prevention (CDC); Health & Human Services, Dept of (HHS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.